Publication | Closed Access

Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study

Hematological MalignancyOncologyGemtuzumab OzogamicinPhase I/ii StudyMedicineMixed-phenotype Acute LeukemiaImmunologyHematologyAnti-cd33 AntibodyImmunotherapyPharmacologyCancer ResearchMyeloid Neoplasia